(
)
168
A. Giuffrida et al.rEuropean Journal of Pharmacology 408 2000 161–168
Ž
.
Cadas, H., di Tomaso, E., Piomelli, D., 1997. Occurrence and biosynthe-
sis of endogenous cannabinoid precursor, N-arachidonoyl-phos-
phatidylethanolamine, in rat brain. J. Neurosci. 17, 1226–1242.
Calignano, A., La Rana, G., Beltramo, M., Makriyannis, A., Piomelli, D.,
1997a. Potentiation of anandamide hypotension by the transport in-
hibitor, AM404. Eur. J. Pharmacol. 337, R1–R2.
Calignano, A., La Rana, G., Makriyannis, A., Lin, S.Y., Beltramo, M.,
Piomelli, D., 1997b. Inhibition of intestinal motility by anandamide,
an endogenous cannabinoid. Eur. J. Pharmacol. 340, R7–R8.
Accumulation of N-arachidonoylethanolamide anandamide into
cerebellar granule cells occurs via facilitated diffusion. J. Neurochem.
69, 631–638.
Jerman, J.C., Brough, S.J., Davis, J.B., Middlemiss, D.N., Smart, D.,
2000. The anandamide transport inhibitor AM404 is an agonist at the
rat vanilloid receptor VR1 . Br. J. Pharmacol. 129, 73 pp.
McLafferty, F.W., Turecek, F., 1993. Interpretation of Mass Spectra.
University Science Books, Sausalito, CA.
Ž
.
Mezey, E., Toth, Z.E., Cortright, D.N., Arzubi, M.K., Krause, J.E., Elde,
´
Calignano, A., La Rana, G., Giuffrida, A., Piomelli, D., 1998. Control of
pain initiation by endogenous cannabinoids. Nature 394, 277–281.
R.A.G., Blumberg, P.M., Szallasi, A., 2000. Distribution of mRNA
Ž
.
for vanilloid receptor subtype 1 VR1 , and VR1-like immunoreactiv-
ity, in the central nervous system of the rat and human. Proc. Natl.
Acad. Sci. U. S. A. 97, 3655–3660.
Calignano, A., Katona, I., Desarnaud, F., Giuffrida, A., La Rana, G.,
´
´
Mackie, K., Freund, T.F., Piomelli, D., 2000. Bidirectional control of
airway responsiveness by endogenous cannabinoids. Nature, in press.
Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A.,
Gilula, N.B., 1996. Molecular characterization of an enzyme that
degrades neuromodulatory fatty-acid amides. Nature 384, 83–87.
Pertwee, R.G., 1997. Pharmacology of cannabinoid CB1 and CB2 recep-
tors. Pharmacol. Ther. 74, 129–180.
Piomelli, D., Beltramo, M., Glasnapp, S., Lin, S.Y., Goutopoulos, A.,
Xie, X.-Q., Makriyannis, A., 1999. Structural determinants for recog-
nition and traslocation by the anandamide transporter. Proc. Natl.
Acad. Sci. U. S. A. 96, 5802–5807.
Desarnaud, F., Cadas, H., Piomelli, D., 1995. Anandamide amidohydro-
´
lase activity in rat brain microsomes: Identification and partial charac-
terization. J. Biol. Chem. 270, 6030–6035.
Piomelli, D., Giuffrida, A., Calignano, A., Rodrıguez de Fonseca, F.,
´
Devane, W., Hanus, L., Breuer, A., Pertwee, R., Stevenson, L., Griffin,
G., Gibson, D., Mandelbaum, D., Etinger, A., Mechoulam, R., 1992.
Isolation and structure of a brain constituent that binds to the cannabi-
noid receptor. Science 258, 1946–1949.
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz,
J.-C., Piomelli, D., 1994. Formation and inactivation of endogenous
cannabinoid anandamide in central neurons. Nature 372, 686–691.
Fride, E., Mechoulam, R., 1993. Pharmacological activity of the cannabi-
noid receptor agonist, anandamide, a brain constituent. Eur. J. Phar-
macol. 231, 313–314.
2000. The endocannabinoid system as a target for therapeutic drugs.
Trends Pharmacol. Sci. 21, 218–224.
Romero, J., de Miguel, R., Garcıa-Palomero, E., Fernandez-Ruiz, J.J.,
´
Ramos, J.A., 1995. Time-course of the effects of anandamide, the
putative endogenous cannabinoid receptor ligand, on extrapyramidal
function. Brain Res. 694, 223–232.
Schmid, P.C., Kuwae, T., Krebsbach, R.J., Schmid, H.H.O., 1997. Anan-
damide and other N-acylethanolamines in mouse peritoneal
macrophages. Chem. Phys. Lipids 87, 103–110.
Siegenthaler, G., 1990. Gel electrophoresis of cellular retinoic acid-bind-
ing protein, cellular retinol-binding protein, and serum retinol-binding
protein. Methods Enzymol. 189, 299–307.
Smart, D., Jerman, J.C., 2000. Anandamide: an endogenous activator of
the vanilloid receptor. Trends Pharmacol. Sci. 21, 134.
Smith, P.B., Compton, D.R., Welch, S.P., Razdan, R.K., Mechoulam, R.,
Martin, B.R., 1994. The pharmacological activity of anandamide, a
putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther.
270, 219–227.
Sugiura, T., Kondo, S., Sukagawa, A., Tonegawa, T., Nakane, S., Ya-
mashita, A., Ishima, Y., Waku, K., 1996. Transacylase-mediated and
phosphodiesterase-mediated synthesis of N-arachidonoylethanola-
mine, an endogenous cannabinoid-receptor ligand, in rat brain micro-
somes. Eur. J. Biochem. 240, 53–62.
Ueda, N., Kurahashi, Y., Yamamoto, S., Tokunaga, T., 1995. Partial
purification and characterization of the porcine brain enzyme hydro-
lyzing and synthesizing anandamide. J. Biol. Chem. 270, 23823–
23827.
Gifford, A.N., Bruneus, M., Lin, S., Goutopoulos, A., Makriyannis, A.,
Volkow, N.D., Gatley, S.J., 1999. Potentiation of the action of
anandamide on hippocampal slices by the fatty acid amide hydrolase
Ž
.
inhibitor, palmitylsulphonyl fluoride AM 374 . Eur. J. Pharmacol.
383, 9–14.
Giuffrida, A., Piomelli, D., 1998. Purification and high-resolution analy-
sis of anandamide and other fatty acylethanolamides. In: Laychock,
Ž
.
S.G., Rubin, R.P. Eds. , Lipid Second Messengers. CRC Press LLC,
Boca Raton, FL, pp. 113–133.
Giuffrida, A., Parsons, L.H., Kerr, T.M., Rodrıguez de Fonseca, F.,
´
Navarro, M., Piomelli, D., 1999. Dopamine activation of endogenous
cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2, 358–363.
Giuffrida, A., Desarnaud, F., Piomelli, D., 2000a. Endogenous cannabi-
´
noid signaling and psychomotor disorders. Prostaglandins Lipid Medi-
ators 61, 63–70.
Giuffrida, A., Rodrıguez de Fonseca, F., Piomelli, D., 2000b. Quantifica-
´
tion of bioactive acylethanolamides in rat plasma by electrospray
mass spectrometry. Anal. Biochem. 280, 87–93.
Wagner, J.A., Varga, K., Ellis, E.F., Rzigalinski, B.A., Martin, B.R.,
Kunos, G., 1997. Activation of peripheral CB1 cannabinoid receptors
in haemorrhagic shock. Nature 390, 518–521.
Gonzalez, S., Romero, J., de Miguel, R., Lastres-Becker, I., Villanua,
´
M.A., Makriyannis, A., Ramos, J.A., Fernandez-Ruiz, J.J., 1999.
´
Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of
the carrier-mediated transport of anandamide. Life Sci. 65, 327–336.
Hillard, C.J., Edgemond, W.S., Jarrahian, A., Campbell, W.B., 1997.
Zygmunt, P.M., Chuang, H., Movahed, P., Julius, D., Hogestatt, E.D.,
¨ ¨
2000. The anandamide transport inhibitor AM404 activates vanilloid
receptors. Eur. J. Pharmacol. 396, 39–42.